GSK gets red light from FDA cancer committee on Blenrep combos

An FDA advisory committee has voted against GSK's Blenrep drug combinations for relapsed or refractory multiple myeloma, citing concerns over its benefit/risk profile at the proposed dosage. This negative recommendation increases uncertainty for the drug's US approval ahead of the July 23, 2025 PDUFA date, despite GSK's confidence and Blenrep's existing approvals in key markets like the UK and Japan, where it addresses a high unmet medical need.

Analysis

GSK faces a significant regulatory setback in the United States following a negative vote from an FDA advisory committee regarding the benefit/risk profile of its Blenrep drug combinations for multiple myeloma. The panel's recommendation against approval, based on the proposed dosage, introduces material uncertainty ahead of the final FDA decision scheduled for the July 23, 2025 PDUFA date. While GSK's management remains publicly confident in the drug's profile, citing the high unmet medical need, this development creates a notable headwind for a key asset in its oncology pipeline. The situation is complicated by the fact that Blenrep combinations have already secured approval in other major markets, including the UK and Japan, based on the same DREAMM-7 and DREAMM-8 trial data, highlighting a potential divergence in regulatory interpretation that investors must now factor into their valuation of the drug's commercial prospects.

Key Decisions for Investors

• Investors should anticipate heightened stock price volatility for GSK leading up to the July 23 PDUFA date, as the negative advisory committee vote represents a significant binary risk for the drug's approval in the US market.
• It is crucial to monitor any further communications from GSK or the FDA regarding potential data resubmissions or dosage adjustments, as these could signal a pathway to mitigate the committee's concerns and alter the drug's approval odds.
• Given the heightened regulatory risk, portfolio managers should reassess their exposure to GSK, and those considering new positions may find it prudent to wait for more clarity post-PDUFA decision or employ hedging strategies to protect against potential downside.